Here’s what you should know.
1. Biolase conducted the study at Washington University in St. Louis. Researchers measured kidney function in health subjects to those with Stage 4 chronic kidney disease.
2. The company used its Transdermal Glomerular Filtration Rate Monitor. The system employs an optical skin sensor and a fluorescent tracer agent to provide physicians with real-time kidney monitoring.
3. MediBeacon CEO Steve Hanley said, “Completion of our clinical study on patients with impaired kidney function represents an important milestone. “
4. MediBeacon is conducting a multicenter, international study of the monitor in the fourth quarter of 2017.
More articles on improving health:
Only 31% of patients support surgeons performing overlapping surgeries: 4 things to know
20 US regions with the most & least medical debt
10 things to know about Regent Surgical Health
